05:45:29 EDT Fri 19 Apr 2024
Enter Symbol
or Name

Login ID:
Nurexone Biologic Inc
Symbol NRX
Shares Issued 55,341,700
Close 2024-02-20 C$ 1.09
Market Cap C$ 60,322,453
Recent Sedar Documents

Nurexone expands IP portfolio with ExoTherapy platform

2024-02-20 16:27 ET - News Release

Dr. Lior Shaltiel reports


Nurexone Biologic Inc. has underscored its expanding intellectual property portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies.

Nurexone's intellectual property portfolio describes the ExoTherapy platform's comprehensive technology and processes for the production of nanodrugs, including large scale production of exosomes, loading of active molecules and the composition of the exosomes themselves. The loading technology was presented to the public in the press release of Feb. 14, 2024. Today, the company is highlighting its innovative bioreactor and biological processes for:

  1. High-yield repeatable production of exosomes;
  2. Production of natural and potent exosomes (not synthetically engineered).

Dr. Lior Shaltiel, chief executive officer of Nurexone, emphasized: "Exosomes are known for their innate regenerative abilities and are becoming increasingly important in both the health care sectors and even aesthetics. With our proprietary production and loading advantages, Nurexone is advancing development of nanodrugs that use exosomes as a biodelivery system, beginning with ExoPTEN. In addition, our ExoTherapy platform is expected to have broad appeal to the pharma industry for a wide range of potential collaborations, which are expected to yield cutting-edge nanodrugs and a stable revenue stream for the company."

Scientific results and initiatives have demonstrated efficiency of the company's large-scale production process, its effectiveness of the company's proprietary small-interfering RNA sequences as therapeutic agent and the technology for loading veracity of therapeutic molecules into exosomes. Aspects of the company's platform which relate to extracellular vesicles production are described in a growing intellectual property portfolio with two PCT applications currently in national phases.

The first application disclosed a unique 3-D porous scaffold that induce physiological changes in the cells, which result in enhanced secretion of EVs and in improved biological effect of the Evs on mammalian cells. This international patent application is currently pending in the United States, European Union, Australia, Singapore and Israel. The second international patent application further elaborates the EV composition produced by the 3-D system, as well as the treatment of diseases and disorders associated with such composition. This international patent application is currently pending in the United States, European Union, Australia, Israel and India.

Both applications, once granted, will provide Nurexone patent protection over unique and effective platform that will maximize EVs quality. These EVs will be used for the development and manufacturing of diverse medicament for various diseases as will be developed by the Nurexone team. Such developments are the basis of additional patent families.

Nurexone has an exclusive licence from the Technion (Israel Institute of Technology) over a novel patent family that claims a system and method for producing extracellular vesicles from stem cells for other types of indications as well. Prof. Shulamit Levenberg, director of the Technion Center for 3D Bioprinting and chief scientific adviser at Nurexone, and her team lab are behind this technology. This patent family bundled together two international patent applications.

About Nurexone Biologic Inc.

Nurexone is a TSX Venture Exchange-listed pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered central nervous system injuries. The company's first product, ExoPTEN for acute spinal cord injury, was proved to recover motor function in 75 per cent of laboratory rats when administered intranasally. ExoPTEN has received orphan drug designation from the Food and Drug Administration with first in human expected in 2025. The Nurexone platform technology is expected to offer novel solutions to drug companies interested in non-invasive targeted drug delivery for other indications.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.